Select Author

Going Through Samples or Re-inventorying? eLearning Modules to Help You Become a Sample Re-inventory Pro

What’s in YOUR Freezer??

Conducting a search and re-inventory of materials in multiple laboratories and biobanks is an intimidating prospect.  Yet in the aftermath of discovering vials containing smallpox and other pathogens in a low-security environment, the National Institutes of Health (NIH) has decided to do just that.

The materials were collected and stored in the 1950s and left in place under conditions deemed appropriate at the time. However, their discovery serves as a wake-up call to all institutions that have been involved in research for multiple decades, and that may also have materials in storage that were stored according to criteria that are now long outdated.

Topic: Biobanking and Biorepository, Content: Blog

Top Clinical Trial Supply Chain Challenges...(and How to Overcome Them)


In her most recent post on the Fisher Clinical Services BlogPam Osborne concludes her series on managing the clinical trial supply chain with a 10-step summary for overcoming the biggest challenges. Even if you're conducting "non-clinical research" that doesn't have a patient as the endpoint, many of the steps she outlines should be followed to ensure your valuable product is kept safe and secure.

Topic: Cold-Chain Logistics, Topic: Clinical Trial..........

Gaining Capacity Through Density: Six Ways to Achieve Effective Storage

Available storage space continues to be a critical issue for every biorepository. In the latest Inside Biobanking blog post "A Forgotten key to Biorepository Efficiency: Maximizing Storage Space", this issue is raised and many good fundamental concepts are introduced to operate a more efficient biobank. In addition, I have found that the following six ideas will lead to gains in storage capacity by increasing storage density, and should be evaluated in every biorepository, whether you manage your own or outsource

Topic: Biobanking and Biorepository, Content: Blog

Defense in Depth: Off-Site Storage for Biological Specimens and Biopharmaceuticals Risk Mitigation

The management of risk is part of all business operations, but to biotech companies manufacturing cell-based therapies, risk mitigation is necessarily a critical element of day-to-day operations.  The costly nature of irreplaceable samples/cell lines and high value products such as cell-based drugs, and biological active pharmaceutical ingredient (Bio-API) dictates planning for the full continuum of risk. The best solution is frequently offsite storage.

Topic: Biobanking and Biorepository, Content: eBoo..........